EUFOREA/EPOS2020 statement on the clinical considerations for chronic rhinosinusitis with nasal polyps care
- Author
- Peter Hellings (UGent) , Isam Alobid, Wilma T. Anselmo‐Lima, Manuel Bernal‐Sprekelsen, Leif Bjermer, Lisa Caulley, Adam Chaker, Jannis Constantinidis, Diego M. Conti, Eugenio De Corso, Martin Desrosiers, Zuzana Diamant, Philippe Gevaert (UGent) , Joseph K. Han, Enrico Heffler, Claire Hopkins, Basile N. Landis, Olga Lourenco, Valerie Lund, Amber U. Luong, Joaquim Mullol, Anju Peters, Carl Philpott, Sietze Reitsma, Dermot Ryan, Glenis Scadding, Brent Senior, Peter Valentin Tomazic, Elina Toskala, Thibaut Van Zele (UGent) , An‐Sofie Viskens, Martin Wagenmann and W. J. Fokkens
- Organization
- Abstract
- Following the European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA) treatment algorithm for chronic rhinosinusitis (CRS) with nasal polyps (CRSwNP), patients suffering from severe uncontrolled CRSwNP are recommended to receive oral corticosteroids, (revision) sinus surgery, systemic biologicals and/or aspirin treatment after desensitization (ATAD). Given the major differences in indications, outcomes, practical considerations, risks and costs of these key pillars of treatment, there is a growing need to define criteria for each treatment option and list the clinically relevant and major considerations for them. This EUFOREA document therefore provides an expert panel overview of the expected outcomes, specific considerations and (contra)indications of the five major treatment arms of severe uncontrolled CRSwNP: oral corticosteroids, primary and revision sinus surgery, biological treatment and ATAD. This overview of treatment considerations is needed to allow physicians and patients to consider the different options in the context of providing optimal and personalized care for severe uncontrolled CRSwNP. In conclusion, the five major treatment options for severe uncontrolled CRSwNP have intrinsic advantages, specific indications and considerations that are of importance to the patient, the physician and the society. This EUFOREA statement supports the unmet need to define criteria for the indication of every treatment pillar of CRSwNP.
- Keywords
- ENDOSCOPIC SINUS SURGERY, ASTHMA, BIOLOGICS, OUTCOMES, METAANALYSIS, RHINITIS, ALLERGY, aspirin intolerance, biologics, corticosteroids, CRSwNP, sinus surgery
Downloads
-
Allergy - 2023 - Hellings - EUFOREA EPOS2020 statement on the clinical considerations for chronic rhinosinusitis with nasal.pdf
- full text (Published version)
- |
- open access
- |
- |
- 3.82 MB
Citation
Please use this url to cite or link to this publication: http://hdl.handle.net/1854/LU-01J1JR6Y1QJWQ2NYS2QEQ5M6VN
- MLA
- Hellings, Peter, et al. “EUFOREA/EPOS2020 Statement on the Clinical Considerations for Chronic Rhinosinusitis with Nasal Polyps Care.” ALLERGY, vol. 79, no. 5, 2024, pp. 1123–33, doi:10.1111/all.15982.
- APA
- Hellings, P., Alobid, I., Anselmo‐Lima, W. T., Bernal‐Sprekelsen, M., Bjermer, L., Caulley, L., … Fokkens, W. J. (2024). EUFOREA/EPOS2020 statement on the clinical considerations for chronic rhinosinusitis with nasal polyps care. ALLERGY, 79(5), 1123–1133. https://doi.org/10.1111/all.15982
- Chicago author-date
- Hellings, Peter, Isam Alobid, Wilma T. Anselmo‐Lima, Manuel Bernal‐Sprekelsen, Leif Bjermer, Lisa Caulley, Adam Chaker, et al. 2024. “EUFOREA/EPOS2020 Statement on the Clinical Considerations for Chronic Rhinosinusitis with Nasal Polyps Care.” ALLERGY 79 (5): 1123–33. https://doi.org/10.1111/all.15982.
- Chicago author-date (all authors)
- Hellings, Peter, Isam Alobid, Wilma T. Anselmo‐Lima, Manuel Bernal‐Sprekelsen, Leif Bjermer, Lisa Caulley, Adam Chaker, Jannis Constantinidis, Diego M. Conti, Eugenio De Corso, Martin Desrosiers, Zuzana Diamant, Philippe Gevaert, Joseph K. Han, Enrico Heffler, Claire Hopkins, Basile N. Landis, Olga Lourenco, Valerie Lund, Amber U. Luong, Joaquim Mullol, Anju Peters, Carl Philpott, Sietze Reitsma, Dermot Ryan, Glenis Scadding, Brent Senior, Peter Valentin Tomazic, Elina Toskala, Thibaut Van Zele, An‐Sofie Viskens, Martin Wagenmann, and W. J. Fokkens. 2024. “EUFOREA/EPOS2020 Statement on the Clinical Considerations for Chronic Rhinosinusitis with Nasal Polyps Care.” ALLERGY 79 (5): 1123–1133. doi:10.1111/all.15982.
- Vancouver
- 1.Hellings P, Alobid I, Anselmo‐Lima WT, Bernal‐Sprekelsen M, Bjermer L, Caulley L, et al. EUFOREA/EPOS2020 statement on the clinical considerations for chronic rhinosinusitis with nasal polyps care. ALLERGY. 2024;79(5):1123–33.
- IEEE
- [1]P. Hellings et al., “EUFOREA/EPOS2020 statement on the clinical considerations for chronic rhinosinusitis with nasal polyps care,” ALLERGY, vol. 79, no. 5, pp. 1123–1133, 2024.
@article{01J1JR6Y1QJWQ2NYS2QEQ5M6VN,
abstract = {{Following the European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA) treatment algorithm for chronic rhinosinusitis (CRS) with nasal polyps (CRSwNP), patients suffering from severe uncontrolled CRSwNP are recommended to receive oral corticosteroids, (revision) sinus surgery, systemic biologicals and/or aspirin treatment after desensitization (ATAD). Given the major differences in indications, outcomes, practical considerations, risks and costs of these key pillars of treatment, there is a growing need to define criteria for each treatment option and list the clinically relevant and major considerations for them. This EUFOREA document therefore provides an expert panel overview of the expected outcomes, specific considerations and (contra)indications of the five major treatment arms of severe uncontrolled CRSwNP: oral corticosteroids, primary and revision sinus surgery, biological treatment and ATAD. This overview of treatment considerations is needed to allow physicians and patients to consider the different options in the context of providing optimal and personalized care for severe uncontrolled CRSwNP. In conclusion, the five major treatment options for severe uncontrolled CRSwNP have intrinsic advantages, specific indications and considerations that are of importance to the patient, the physician and the society. This EUFOREA statement supports the unmet need to define criteria for the indication of every treatment pillar of CRSwNP.}},
author = {{Hellings, Peter and Alobid, Isam and Anselmo‐Lima, Wilma T. and Bernal‐Sprekelsen, Manuel and Bjermer, Leif and Caulley, Lisa and Chaker, Adam and Constantinidis, Jannis and Conti, Diego M. and De Corso, Eugenio and Desrosiers, Martin and Diamant, Zuzana and Gevaert, Philippe and Han, Joseph K. and Heffler, Enrico and Hopkins, Claire and Landis, Basile N. and Lourenco, Olga and Lund, Valerie and Luong, Amber U. and Mullol, Joaquim and Peters, Anju and Philpott, Carl and Reitsma, Sietze and Ryan, Dermot and Scadding, Glenis and Senior, Brent and Tomazic, Peter Valentin and Toskala, Elina and Van Zele, Thibaut and Viskens, An‐Sofie and Wagenmann, Martin and Fokkens, W. J.}},
issn = {{0105-4538}},
journal = {{ALLERGY}},
keywords = {{ENDOSCOPIC SINUS SURGERY,ASTHMA,BIOLOGICS,OUTCOMES,METAANALYSIS,RHINITIS,ALLERGY,aspirin intolerance,biologics,corticosteroids,CRSwNP,sinus surgery}},
language = {{eng}},
number = {{5}},
pages = {{1123--1133}},
title = {{EUFOREA/EPOS2020 statement on the clinical considerations for chronic rhinosinusitis with nasal polyps care}},
url = {{http://doi.org/10.1111/all.15982}},
volume = {{79}},
year = {{2024}},
}
- Altmetric
- View in Altmetric
- Web of Science
- Times cited: